333 related articles for article (PubMed ID: 24385259)
1. Systematic assessment of decision-analytic models for chronic myeloid leukemia.
Rochau U; Schwarzer R; Jahn B; Sroczynski G; Kluibenschaedl M; Wolf D; Radich J; Brixner D; Gastl G; Siebert U
Appl Health Econ Health Policy; 2014 Apr; 12(2):103-15. PubMed ID: 24385259
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Rochau U; Sroczynski G; Wolf D; Schmidt S; Jahn B; Kluibenschaedl M; Conrads-Frank A; Stenehjem D; Brixner D; Radich J; Gastl G; Siebert U
Leuk Lymphoma; 2015; 56(8):2315-25. PubMed ID: 25393806
[TBL] [Abstract][Full Text] [Related]
3. Economic Evaluations of Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia in Middle- and High-Income Countries: A Systematic Review.
Fu J; Liu Y; Lin H; Wu B
Clin Drug Investig; 2018 Dec; 38(12):1167-1178. PubMed ID: 30232698
[TBL] [Abstract][Full Text] [Related]
4. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.
Skrepnek GH; Ballard EE
Pharmacotherapy; 2005 Mar; 25(3):325-34. PubMed ID: 15843279
[TBL] [Abstract][Full Text] [Related]
5. Medical decision analysis for first-line therapy of chronic myeloid leukemia.
Rochau U; Sroczynski G; Wolf D; Schmidt S; Conrads-Frank A; Jahn B; Saverno K; Brixner D; Radich J; Gastl G; Siebert U
Leuk Lymphoma; 2014 Aug; 55(8):1758-67. PubMed ID: 24160847
[TBL] [Abstract][Full Text] [Related]
6. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
Ghatnekar O; Hjalte F; Taylor M
Acta Oncol; 2010 Aug; 49(6):851-8. PubMed ID: 20615173
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
Padula WV; Larson RA; Dusetzina SB; Apperley JF; Hehlmann R; Baccarani M; Eigendorff E; Guilhot J; Guilhot F; Hehlmann R; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Saussele S; Schiffer CA; Silver RT; Simonsson B; Conti RM
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26944912
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia.
Liberato NL; Quaglini S; Barosi G
J Clin Oncol; 1997 Jul; 15(7):2673-82. PubMed ID: 9215840
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J; Alvarez MA; Torres A
Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
Warren E; Ward S; Gordois A; Scuffham P
Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
[TBL] [Abstract][Full Text] [Related]
13. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis.
Lee SJ; Kuntz KM; Horowitz MM; McGlave PB; Goldman JM; Sobocinski KA; Hegland J; Kollman C; Parsons SK; Weinstein MC; Weeks JC; Antin JH
Ann Intern Med; 1997 Dec; 127(12):1080-8. PubMed ID: 9412310
[TBL] [Abstract][Full Text] [Related]
14. Decision-Analytic Modeling Studies in Prevention and Treatment of Iodine Deficiency and Thyroid Disorders: A Systematic Overview.
Rochau U; Qerimi Rushaj V; Schaffner M; Schönhensch M; Stojkov I; Jahn B; Hubalewska-Dydejczyk A; Erlund I; Thuesen BH; Zimmermann M; Moreno-Reyes R; Lazarus JH; Völzke H; Siebert U
Thyroid; 2020 May; 30(5):746-758. PubMed ID: 31964247
[No Abstract] [Full Text] [Related]
15. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
Stansfield L; Hughes TE; Walsh-Chocolaad TL
Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
[TBL] [Abstract][Full Text] [Related]
16. Systematic assessment of decision models in Parkinson's disease.
Siebert U; Bornschein B; Walbert T; Dodel RC
Value Health; 2004; 7(5):610-26. PubMed ID: 15367256
[TBL] [Abstract][Full Text] [Related]
17. Decision-analytic modeling studies: An overview for clinicians using multiple myeloma as an example.
Rochau U; Jahn B; Qerimi V; Burger EA; Kurzthaler C; Kluibenschaedl M; Willenbacher E; Gastl G; Willenbacher W; Siebert U
Crit Rev Oncol Hematol; 2015 May; 94(2):164-78. PubMed ID: 25620327
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia.
Kattan MW; Inoue Y; Giles FJ; Talpaz M; Ozer H; Guilhot F; Zuffa E; Huber SL; Beck JR
Ann Intern Med; 1996 Oct; 125(7):541-8. PubMed ID: 8815752
[TBL] [Abstract][Full Text] [Related]
19. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.
Chhatwal J; He T; Lopez-Olivo MA
Pharmacoeconomics; 2016 Jun; 34(6):551-67. PubMed ID: 26748919
[TBL] [Abstract][Full Text] [Related]
20. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
